174 related articles for article (PubMed ID: 35888580)
41. The kinetic profiles of copeptin and mid regional proadrenomedullin (MR-proADM) in pediatric lower respiratory tract infections.
Baumann P; Fuchs A; Gotta V; Ritz N; Baer G; Bonhoeffer JM; Buettcher M; Heininger U; Szinnai G; Bonhoeffer J;
PLoS One; 2022; 17(3):e0264305. PubMed ID: 35271609
[TBL] [Abstract][Full Text] [Related]
42. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
[TBL] [Abstract][Full Text] [Related]
43. Adrenomedullin Is Associated With Surgical Trauma and Impaired Renal Function in Vascular Surgery Patients.
Gillmann HJ; Meinders A; Larmann J; Sahlmann B; Schrimpf C; Aper T; Lichtinghagen R; Teebken OE; Theilmeier G
J Intensive Care Med; 2019 Jan; 34(1):67-76. PubMed ID: 28110613
[TBL] [Abstract][Full Text] [Related]
44. Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights.
Haig C; Carrick D; Carberry J; Mangion K; Maznyczka A; Wetherall K; McEntegart M; Petrie MC; Eteiba H; Lindsay M; Hood S; Watkins S; Davie A; Mahrous A; Mordi I; Ahmed N; Teng Yue May V; Ford I; Radjenovic A; Welsh P; Sattar N; Oldroyd KG; Berry C
JACC Cardiovasc Imaging; 2019 Jun; 12(6):993-1003. PubMed ID: 30031700
[TBL] [Abstract][Full Text] [Related]
45. MR-Proadrenomedullin as biomarker of renal damage in urinary tract infection in children.
Peñalver Penedo R; Rupérez Lucas M; Álvarez-Sala Walther LA; Torregrosa Benavent A; Casas Losada ML; Bañuelos Andrio L; Rebolledo Poves AB; Bueno Campaña M
BMC Pediatr; 2021 Jun; 21(1):292. PubMed ID: 34187408
[TBL] [Abstract][Full Text] [Related]
46. Synergistic effect of myocardial injury and mid-regional proAdrenomedullin elevation in determining clinical outcomes of SARS-CoV-2 patients.
Spoto S; Mangiacapra F; D'Avanzo G; Lemme D; Bustos Guillén C; Abbate A; Markley JD; Sambuco F; Markley R; Fogolari M; Locorriere L; Lupoi DM; Battifoglia G; Costantino S; Ciccozzi M; Angeletti S
Front Med (Lausanne); 2022; 9():929408. PubMed ID: 36388948
[TBL] [Abstract][Full Text] [Related]
47. Endothelial dysfunction and Mid-Regional proAdrenomedullin: What role in SARS-CoV-2 infected Patients?
Zaninotto M; Mion MM; Marchioro L; Padoan A; Plebani M
Clin Chim Acta; 2021 Dec; 523():185-190. PubMed ID: 34555411
[TBL] [Abstract][Full Text] [Related]
48. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.
Christ-Crain M; Morgenthaler NG; Struck J; Harbarth S; Bergmann A; Müller B
Crit Care; 2005; 9(6):R816-24. PubMed ID: 16356231
[TBL] [Abstract][Full Text] [Related]
49. Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-30).
Landman GW; van Dijk PR; Drion I; van Hateren KJ; Struck J; Groenier KH; Gans RO; Bilo HJ; Bakker SJ; Kleefstra N
Diabetes Care; 2014; 37(3):839-45. PubMed ID: 24170764
[TBL] [Abstract][Full Text] [Related]
50. Mid-regional proadrenomedullin levels predict recurrence of atrial fibrillation after catheter ablation.
Parwani AS; von Haehling S; Kolodziejski AI; Huemer M; Wutzler A; Attanasio P; Stojakovic T; Scharnagl H; Haverkamp W; Boldt LH
Int J Cardiol; 2015 Feb; 180():129-33. PubMed ID: 25438233
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective study.
Montrucchio G; Sales G; Balzani E; Lombardo D; Giaccone A; Cantù G; D'Antonio G; Rumbolo F; Corcione S; Simonetti U; Bonetto C; Zanierato M; Fanelli V; Filippini C; Mengozzi G; Brazzi L
Front Med (Lausanne); 2023; 10():1122367. PubMed ID: 37035317
[TBL] [Abstract][Full Text] [Related]
52. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
[TBL] [Abstract][Full Text] [Related]
53. Endothelium-associated biomarkers mid-regional proadrenomedullin and C-terminal proendothelin-1 have good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: A prospective cohort study.
van Oers JAH; Kluiters Y; Bons JAP; de Jongh M; Pouwels S; Ramnarain D; de Lange DW; de Grooth HJ; Girbes ARJ
J Crit Care; 2021 Dec; 66():173-180. PubMed ID: 34340901
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of platelet/lymphocyte ratio and CAMI-STEMI score for major adverse cardiac events in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: A prospective observational study.
Wang Y; Peng Z
Medicine (Baltimore); 2021 Aug; 100(33):e26942. PubMed ID: 34414954
[TBL] [Abstract][Full Text] [Related]
55. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study.
Haag E; Gregoriano C; Molitor A; Kloter M; Kutz A; Mueller B; Schuetz P
Clin Chem Lab Med; 2021 May; 59(6):1165-1176. PubMed ID: 33554514
[TBL] [Abstract][Full Text] [Related]
56. Interleukin-18 levels on admission are associated with mid-term adverse clinical events in patients with ST-segment elevation acute myocardial infarction undergoing percutaneous coronary intervention.
Gao Y; Tong GX; Zhang XW; Leng JH; Jin JF; Wang NF; Yang JM
Int Heart J; 2010 Mar; 51(2):75-81. PubMed ID: 20379038
[TBL] [Abstract][Full Text] [Related]
57. Acute Response in the Noninfarcted Myocardium Predicts Long-Term Major Adverse Cardiac Events After STEMI.
Shanmuganathan M; Masi A; Burrage MK; Kotronias RA; Borlotti A; Scarsini R; Banerjee A; Terentes-Printzios D; Zhang Q; Hann E; Tunnicliffe E; Lucking A; Langrish J; Kharbanda R; De Maria GL; Banning AP; Choudhury RP; Channon KM; Piechnik SK; Ferreira VM;
JACC Cardiovasc Imaging; 2023 Jan; 16(1):46-59. PubMed ID: 36599569
[TBL] [Abstract][Full Text] [Related]
58. Incidence and Predictors of Adverse Events Among Initially Stable ST-Elevation Myocardial Infarction Patients Following Primary Percutaneous Coronary Intervention.
Amon J; Wong GC; Lee T; Singer J; Cairns J; Shavadia JS; Granger C; Gin K; Wang TY; van Diepen S; Fordyce CB
J Am Heart Assoc; 2022 Sep; 11(17):e025572. PubMed ID: 36056738
[TBL] [Abstract][Full Text] [Related]
59. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
[TBL] [Abstract][Full Text] [Related]
60. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker?
Potocki M; Ziller R; Mueller C
Curr Heart Fail Rep; 2012 Sep; 9(3):244-51. PubMed ID: 22733501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
